Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
JUPITER, Fla. - Dyadic International, Inc. (NASDAQ:DYAI) announced Wednesday it will begin operating under the name Dyadic Applied BioSolutions in 30 days, signaling a strategic shift from research to commercial operations. The company, currently valued at $28.92 million, is trading near its 52-week low of $0.91, though InvestingPro analysis suggests the stock may be undervalued.
The biotechnology company, which specializes in protein production platforms, is repositioning to concentrate on non-therapeutic proteins for life sciences, food, nutrition, and industrial biotechnology applications through its C1 and Dapibus gene expression technologies.
"As we evolve from licensing our technology in support of therapeutic and vaccine development into a revenue-focused bioprocessing protein platform business, our C1 and Dapibus production platforms remain the engines we expect to drive commercial execution," said Joe Hazelton, President and Chief Operating Officer.
The company recently received a $250,000 milestone payment for progress on its second non-animal dairy enzyme program, highlighting its commercial advancement. Dyadic also secured a second $1.5 million installment from a $3 million Gates Foundation grant to develop low-cost monoclonal antibodies for diseases including malaria and RSV. Financial data from InvestingPro shows the company’s revenue grew 57.59% over the last twelve months, with a strong current ratio of 3.98 indicating solid short-term liquidity.
The rebranding reflects Dyadic’s strategy to pursue commercial opportunities with fewer regulatory hurdles than therapeutic biologics, potentially enabling faster revenue generation and broader market access.
According to the company statement, Dyadic remains on track to commercialize its input proteins in 2025. Its technology platforms utilize the fungal host Thermothelomyces heterothallica, which the company describes as industrially proven and GRAS-accepted (Generally Recognized As Safe). For deeper insights into Dyadic’s financial health and growth potential, investors can access comprehensive analysis and additional ProTips through InvestingPro’s detailed research reports.
The company’s proprietary C1 Expression System aims to deliver engineered proteins and production strains for life sciences and pharmaceutical applications, while its Dapibus platform is being developed for food, nutrition, and industrial applications. Despite reporting a net loss in the last twelve months, the company maintains a moderate debt level and strong liquid assets position.
This announcement was made in a company press release.
In other recent news, Dyadic International reported its first-quarter 2025 financial results, revealing a net loss of $0.07 per share, which aligned with expectations. Revenue for the quarter was $393,570, slightly below the forecast of $394,000, but an increase from $335,000 in the same quarter last year. The company is focusing on non-pharmaceutical product launches, including recombinant human serum albumin, with upcoming launches anticipated in Q3 2025. Dyadic has appointed Joe Hazelton as its new President, aiming to drive growth in various markets, including life sciences and nutrition. The company has also reduced its number of paid collaborators from nine to four, indicating a strategic pivot. Additionally, Dyadic shareholders approved board proposals at the recent annual meeting, including the election of Mark A. Emalfarb as a Class III director. The appointment of Crowe LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, was ratified. These developments reflect Dyadic’s ongoing transformation and strategic focus on product commercialization.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.